Startups
“One treatment a year. Life changing.”
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery.
This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery.
This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.
Overview
Location
United Kingdom, England, Oxford
Employees
11-50
Total raised
$37M
Founded date
2014
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| V-Bio Ventures | v-bio.ventures | |
| Jan 12, 2023 | Forbion | forbion.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 1, 2021 | Oxular raises $37 million | Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that it has completed a $37 million (£27 million) financing led by Forbion. Proceeds will fund planned further clinical development of its lead a... |
| Mar 1, 2021 | Oxular Ltd - Oxular raises $37 million | Led by specialist life sciences investor, Forbion Investment will fund Phase 2 human clinical studies evaluating Oxular's 12-month treatment for diabetic macular edema, and accelerate development of early-product pipeline Oxular Lim... |
Reviews 0
FAQ about Oxular
When was Oxular founded?
Oxular was founded in 2014.
How much funding has Oxular raised?
Oxular has raised $37M in total across 1 funding round.
Who has invested in Oxular?
Parsers VC lists 3 investors of Oxular, among them Forbion and V-Bio Ventures.
What has the press written about Oxular?
Parsers VC has collected 3 articles mentioning Oxular, among them “Oxular raises $37 million” (Mar 1, 2021) and “Oxular Ltd - Oxular raises $37 million” (Mar 1, 2021).
Is Oxular still active?
Yes, Oxular is active; its latest activity on Parsers VC dates from Jun 7, 2021.